CA2990012A1 - Antibodies to cd40 - Google Patents

Antibodies to cd40 Download PDF

Info

Publication number: CA2990012A1
Authority: CA; Canada
Prior art keywords: antibody; seq; antibodies; residues; cancer
Prior art date: 2015-06-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA2990012A

Other languages

English (en)

French (fr)

Inventor

Bryan C. Barnhart

Brigitte Devaux

Aaron P. Yamniuk

Shannon L. Okada

Brenda L. Stevens

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-29

Filing date

2016-06-28

Publication date

2017-01-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56322325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2990012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-06-28 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2017-01-05 Publication of CA2990012A1 publication Critical patent/CA2990012A1/en

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2990012A 2015-06-29 2016-06-28 Antibodies to cd40 Pending CA2990012A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562186076P	2015-06-29	2015-06-29
US62/186,076		2015-06-29
US201562252615P	2015-11-09	2015-11-09
US62/252,615		2015-11-09
PCT/US2016/039754 WO2017004006A1 (en)	2015-06-29	2016-06-28	Antibodies to cd40

Publications (1)

Publication Number	Publication Date
CA2990012A1 true CA2990012A1 (en)	2017-01-05

Family

ID=56322325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2990012A Pending CA2990012A1 (en)	2015-06-29	2016-06-28	Antibodies to cd40

Country Status (18)

Country	Link
US (4)	US20180142030A1 (es)
EP (1)	EP3313880B1 (es)
JP (2)	JP7350467B2 (es)
KR (1)	KR102671348B1 (es)
CN (2)	CN115838427A (es)
AU (2)	AU2016285913B2 (es)
BR (1)	BR112017027549A2 (es)
CA (1)	CA2990012A1 (es)
CL (2)	CL2017003427A1 (es)
CO (1)	CO2018000809A2 (es)
EA (1)	EA035268B1 (es)
ES (1)	ES3039629T3 (es)
HK (1)	HK1252666A1 (es)
IL (1)	IL256499B (es)
MX (2)	MX395257B (es)
PE (1)	PE20180315A1 (es)
WO (1)	WO2017004006A1 (es)
ZA (1)	ZA201708704B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012125569A2 (en)	2011-03-11	2012-09-20	Beth Israel Deaconess Medical Center, Inc.	Anti-cd40 antibodies and uses thereof
KR102443258B1 (ko)	2014-08-12	2022-09-14	엘리게이터 바이오사이언스 에이비	항 cd40 항체에 의한 병용 치료제
EA201890162A1 (ru) *	2015-06-29	2018-07-31	Бристол-Маерс Сквибб Компани	Антитела к cd40 с повышенной агонистической активностью
SI3307322T1 (sl)	2015-09-04	2021-08-31	Primatope Therapeutics Inc.	Humanizirana protitelesa proti CD40 in njihove uporabe
EP4406550A3 (en)	2016-03-04	2024-10-16	The Rockefeller University	Antibodies to cd40 with enhanced agonist activity
FI3468997T3 (fi)	2016-06-08	2023-10-31	Xencor Inc	Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een
WO2017220989A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Anti-pd-l1 and il-2 cytokines
CN110621697B (zh)	2017-05-25	2023-06-27	百时美施贵宝公司	拮抗性cd40单克隆抗体及其用途
JP7257971B6 (ja)	2017-06-01	2023-07-24	江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司	抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
KR102813744B1 (ko)	2017-12-27	2025-05-28	브리스톨-마이어스 스큅 컴퍼니	항-cd40 항체 및 그의 용도
JP7059388B2 (ja) *	2018-03-23	2022-04-25	イーライリリーアンドカンパニー	抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体
AU2018432434B2 (en)	2018-07-20	2025-11-20	Eucure (Beijing) Biopharma Co., Ltd	Anti-CD40 antibodies and uses thereof
US20210238287A1 (en) *	2018-07-26	2021-08-05	Bristol-Myers Squibb Company	LAG-3 Combination Therapy for the Treatment of Cancer
AR117091A1 (es)	2018-11-19	2021-07-07	Bristol Myers Squibb Co	Anticuerpos monoclonales antagonistas contra cd40 y sus usos
MX2021005823A (es)	2018-11-30	2021-07-15	Jiangsu Hengrui Medicine Co	Anticuerpo anti-cd40, fragmento de union a antigeno y uso farmaceutico del mismo.
CN112839961B (zh)	2018-11-30	2023-04-04	江苏恒瑞医药股份有限公司	一种cd40抗体药物组合物及其用途
US10570210B1 (en) *	2019-03-04	2020-02-25	Beijing Mabworks Biotech Co.Ltd	Antibodies binding CD40 and uses thereof
SG11202111188VA (en)	2019-04-10	2021-11-29	Univ Nankai	Anti-cd40 antibody and use thereof
KR20220151189A (ko)	2020-03-09	2022-11-14	브리스톨-마이어스 스큅 컴퍼니	증진된 효능제 활성을 갖는 cd40에 대한 항체
AU2021268885B2 (en) *	2020-05-06	2025-02-20	Navicure Biopharmaceuticals Limited	Fusion proteins for immunotherapy against cancer and infectious diseases
CN115403670A (zh) *	2021-05-26	2022-11-29	安徽瀚海博兴生物技术有限公司	抗cd40抗体及其用途
EP4384276A4 (en) *	2021-08-10	2025-06-25	Apexigen, Inc.	Biomarkers for cd40 agonist therapy
US12234294B2 (en)	2021-11-05	2025-02-25	Kiniksa Pharmaceuticals, Gmbh	Pharmaceutical composition of a humanized anti-CD40 antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US8188231B2 (en)	2002-09-27	2012-05-29	Xencor, Inc.	Optimized FC variants
CA3167037A1 (en) *	2010-12-20	2012-06-28	The Rockefeller University	Modulating agonistic tnfr antibodies
CN112812184A (zh)	2011-02-25	2021-05-18	中外制药株式会社	FcγRIIb特异性Fc抗体
CA2923591A1 (en)	2013-12-20	2015-06-25	F. Hoffmann-La Roche Ag	Combination therapy with an anti-ang2 antibody and a cd40 agonist
CN107172880B (zh)	2014-03-24	2021-09-28	癌症研究技术有限公司	含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
US20170233485A1 (en) *	2014-08-18	2017-08-17	Biogen Ma Inc.	Anti-cd40 antibodies and uses thereof
EA201890162A1 (ru) *	2015-06-29	2018-07-31	Бристол-Маерс Сквибб Компани	Антитела к cd40 с повышенной агонистической активностью
EP4406550A3 (en) *	2016-03-04	2024-10-16	The Rockefeller University	Antibodies to cd40 with enhanced agonist activity

2016
- 2016-06-28 EP EP16734545.3A patent/EP3313880B1/en active Active
- 2016-06-28 KR KR1020187002285A patent/KR102671348B1/ko active Active
- 2016-06-28 BR BR112017027549-0A patent/BR112017027549A2/pt not_active IP Right Cessation
- 2016-06-28 JP JP2017568273A patent/JP7350467B2/ja active Active
- 2016-06-28 CA CA2990012A patent/CA2990012A1/en active Pending
- 2016-06-28 MX MX2017016253A patent/MX395257B/es unknown
- 2016-06-28 PE PE2017002834A patent/PE20180315A1/es unknown
- 2016-06-28 ES ES16734545T patent/ES3039629T3/es active Active
- 2016-06-28 US US15/579,450 patent/US20180142030A1/en not_active Abandoned
- 2016-06-28 HK HK18111973.8A patent/HK1252666A1/zh unknown
- 2016-06-28 CN CN202211190048.4A patent/CN115838427A/zh active Pending
- 2016-06-28 EA EA201890175A patent/EA035268B1/ru not_active IP Right Cessation
- 2016-06-28 AU AU2016285913A patent/AU2016285913B2/en not_active Ceased
- 2016-06-28 CN CN201680037548.0A patent/CN107771184B/zh active Active
- 2016-06-28 WO PCT/US2016/039754 patent/WO2017004006A1/en not_active Ceased
2017
- 2017-12-13 MX MX2022002504A patent/MX2022002504A/es unknown
- 2017-12-20 ZA ZA2017/08704A patent/ZA201708704B/en unknown
- 2017-12-22 IL IL256499A patent/IL256499B/en unknown
- 2017-12-28 CL CL2017003427A patent/CL2017003427A1/es unknown
2018
- 2018-01-26 CO CONC2018/0000809A patent/CO2018000809A2/es unknown
2019
- 2019-04-30 US US16/399,379 patent/US10844130B2/en active Active
2020
- 2020-11-06 US US17/091,375 patent/US20210054091A1/en not_active Abandoned
2021
- 2021-10-21 JP JP2021172355A patent/JP2022028666A/ja active Pending
2022
- 2022-05-04 CL CL2022001189A patent/CL2022001189A1/es unknown
- 2022-09-08 AU AU2022228155A patent/AU2022228155A1/en not_active Abandoned
2024
- 2024-04-19 US US18/640,480 patent/US20240336695A1/en active Pending

Also Published As

Publication number	Publication date
IL256499A (en)	2018-02-28
CN107771184B (zh)	2022-11-01
HK1252666A1 (zh)	2019-05-31
KR102671348B1 (ko)	2024-05-30
PE20180315A1 (es)	2018-02-09
IL256499B (en)	2021-12-01
US20240336695A1 (en)	2024-10-10
CL2022001189A1 (es)	2023-01-20
JP7350467B2 (ja)	2023-09-26
ES3039629T3 (en)	2025-10-23
KR20180021834A (ko)	2018-03-05
BR112017027549A2 (pt)	2018-09-11
JP2018526978A (ja)	2018-09-20
MX2017016253A (es)	2018-04-20
EP3313880B1 (en)	2025-08-06
US20210054091A1 (en)	2021-02-25
US20190248911A1 (en)	2019-08-15
EA035268B1 (ru)	2020-05-22
MX2022002504A (es)	2022-04-06
JP2022028666A (ja)	2022-02-16
EP3313880A1 (en)	2018-05-02
ZA201708704B (en)	2019-08-28
CO2018000809A2 (es)	2018-04-19
AU2016285913A1 (en)	2018-02-15
CL2017003427A1 (es)	2018-05-04
CN115838427A (zh)	2023-03-24
US10844130B2 (en)	2020-11-24
AU2022228155A1 (en)	2022-11-10
US20180142030A1 (en)	2018-05-24
WO2017004006A1 (en)	2017-01-05
EA201890175A1 (ru)	2018-06-29
MX395257B (es)	2025-03-25
CN107771184A (zh)	2018-03-06
AU2016285913B2 (en)	2022-06-16

Publication	Publication Date	Title
US20240336695A1 (en)	2024-10-10	Antibodies to cd40
US20200071412A1 (en)	2020-03-05	Antibodies to cd40 with enhanced agonist activity
JP2025128184A (ja)	2025-09-02	Ｔｉｇｉｔに対する抗体
CA3016534A1 (en)	2017-09-08	Antibodies to cd40 with enhanced agonist activity
CA2971732C (en)	2025-09-16	Antibodies to tigit
EA040302B1 (ru)	2022-05-18	Антитела к cd40

Legal Events

Date	Code	Title	Description
2021-04-12	EEER	Examination request	Effective date: 20210326
2022-05-05	EEER	Examination request	Effective date: 20210326
2022-09-14	EEER	Examination request	Effective date: 20210326
2022-12-23	EEER	Examination request	Effective date: 20210326
2023-04-04	EEER	Examination request	Effective date: 20210326
2023-10-14	EEER	Examination request	Effective date: 20210326